Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Gene Bridges: Life as a Self-Funded Biotech




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Gene Bridges: Life as a Self-Funded Biotech
Released on: July 01, 2007. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Fintan Walton talks to Tim Zeppenfeld, Business Development Manager, Gene Bridges, about life as a self-funded and profitable biotechnology company.
  • Summary
  • Transcript
  • Participants
  • Company
Fintan Walton talks to Tim Zeppenfeld, Business Development Manager, Gene Bridges, about life as a self-funded and profitable biotechnology company. Tim tells Fintan about Gene Bridges' Red/ET technology and describes the licensing, fee-for-service and kit distribution business models that the company is following. They discuss Gene Bridge's alliance with BASF, and Tim emphasises the importance of this alliance as a model for an evolving relationship from fee-for-service to a fully blown collaboration. Highlighting Gene Bridge's unusual position as a self-funded and profitable emerging biotechnology company, Tim shares his thoughts on the consolidation of the biotech sector in Germany, and speculates as to Gene Bridges' future strategy.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Dr Tim Zeppenfeld obtained his MSc in Biology at the University of Osnabrueck in 1996. After receiving his PhD in 2000 he joined BASF-LYNX Bioscience in Heidelberg as staff scientist. He worked in the technology department and was responsible for developing new transcriptional profiling tools. In 2005 he joined Gene Bridges as senior scientist and is now responsible for the business development activities at Gene Bridges.
Ganymed Pharma